Salarius Pharmaceuticals (NASDAQ:SLRX – Get Rating) will be announcing its earnings results after the market closes on Friday, August 5th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.
Salarius Pharmaceuticals (NASDAQ:SLRX – Get Rating) last announced its earnings results on Thursday, May 12th. The company reported ($0.13) EPS for the quarter. On average, analysts expect Salarius Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Salarius Pharmaceuticals Trading Up 8.5 %
Shares of SLRX opened at $0.18 on Thursday. Salarius Pharmaceuticals has a 12 month low of $0.16 and a 12 month high of $1.20. The firm’s 50 day moving average is $0.20 and its 200-day moving average is $0.30. The stock has a market capitalization of $10.35 million, a PE ratio of -0.50 and a beta of 1.13.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
Read More
- Get a free copy of the StockNews.com research report on Salarius Pharmaceuticals (SLRX)
- There Are Different Types of Stock To Invest In
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- Two High-Yield Deep-Values You Shouldn’t Ignore
- PayPal Continues To Struggle As Competition Increases
- Is Starbucks Shooting For The Moon?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.